Events | 2023.07.05
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with...
For more information, please visit
https://www.prnewswire.com/news-releases[...]rporate-updates-301870664.html
